NRSN

NeuroSense Therapeutics (NRSN)

About NeuroSense Therapeutics (NRSN)

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Details

Daily high

$0.86

Daily low

$0.82

Price at open

$0.85

52 Week High

$2.60

52 Week Low

$0.63

Market cap

29.2M

Dividend yield

0.00%

Volume

43,379

Avg. volume

148,430

P/E ratio

-1.41

NeuroSense Therapeutics News